Articles related to CARDIOVASCULAR EVENTS

Post-trial analysis reveals a 13% relative reduction in cardiovascular death and kidney disease progression risk, though this benefit primarily manifests in the first 12 months after treatment discontinuation.

A landmark analysis shows that physiology-guided complete revascularization reduced adverse outcomes by approximately 25% compared to culprit-only strategy across both STEMI and NSTEMI patients.

Analysis of 285,680 patients shows a 1.03-1.38% reduction in cumulative mortality with rosuvastatin compared to atorvastatin, alongside varying risks for cardiovascular events, liver outcomes, and diabetes.

Clinical research demonstrates that erythritol consumption increases blood levels by more than 1,000 times and enhances platelet responsiveness in healthy volunteers, potentially elevating cardiovascular risk in susceptible populations.

In a comprehensive Bayesian network meta-analysis, 1 month of DAPT followed by potent P2Y12 inhibitor monotherapy was associated with a significant reduction in major bleeding compared to the conventional 12 months of DAPT, without an increase in MACCE.

Bempedoic acid reduced major adverse cardiovascular events by 13% compared to placebo in statin-intolerant patients, with efficacy comparable to statins when normalized for LDL-C reduction.